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Abstract: Several amino phenyl benzothiazoles were prepared with a view to using them as amyloid 
binding agents for imaging β-amyloid in Alzheimer’s disease. These precursors were radiolabeled 
with 11C-positron-emitting radioisotope using an automated synthesizer and selected radiolabeled 
compounds were further purified by HPLC. Our results demonstrate that changes in structure have a 
major influence on the radioactive yield and the ease with which the radiolabel can be introduced. 
Amino phenyl benzothiazoles with an attached isopropyl group resisted dialkylation perhaps due to 
steric hindrance caused by this group. Straight chain attachment of methyl, ethyl, butyl and crotyl 
groups in the structure decreased the radiochemical yield. Notably, the o-amino phenyl 
benzothiazole derivatives were difficult to alkylate despite stringent experimental conditions. This 
reactivity difference is attributed to the hydrogen bonding characteristics of the o-amino group with 
the nitrogen atom of the thiazole ring.  
Introduction: Dementia is a generic term used to describe a collection of conditions which lead to 
the progressive loss of cognitive function. Presently 30 million people worldwide are affected and 
this number is expected1 to rise to over 80 million by 2050. The most common form of dementia is 
Alzheimer’s disease (AD) accounting for 50-70% of all cases2. Progressive neuronal loss occurs in AD 
and the formation of -amyloid plaques and neurofibrillary tangles within the brain tissue have been 
hypothesised to play a role in pathogenesis3-5. Efforts to develop imaging agents to aid the diagnosis 
of AD and monitor its progression have focussed on small molecules that bind to the Aβ-amyloid 
peptide.  
In the past decade, benzothiazole derivatives have been found to exhibit remarkable selectivity 
towards amyloid and several aminophenyl benzothiazole derivatives have been investigated as 
potential imaging probes. Todd et al10 provide a comprehensive review of the development of these 
compounds for amyloid imaging. The [11C]-6-Me-BTA was prepared by methylation of 4-(6-methyl-2-
benzothiazolyl) aniline using [11C] methyl iodide11. Additional modification by elimination of the 6-
methyl group in the structure gave [11C]BTA which showed improved uptake and washout 
characteristics in normal mice and specific amyloid binding in transgenic mice in vivo and in human 
AD brain homogenates12,13. The 6-hydroxy substituted amino methyl benzothiazole derivative is one 
of the most successful radiolabeled imaging probes to date and has been named as Pittsburgh 
Compound B (PIB).14-24  Here we describe the synthesis, characterization and 11C- radiolabeling of 
aminophenyl benzothiazole derivatives as an extension to previously described compounds.  We 
introduced alkyl groups on the amino arm in the structure of the PIB compound and examined the 
reactivity towards alkylation. The rationale for examining the o-aminophenyl benzothiazole 
compounds is to investigate the presence of intramolecular hydrogen bonds which may confer a 
more planar molecular structure which is thought to be important for binding to amyloid plaques. 
These intramolecular hydrogen bonds are lacking in p-aminophenyl benzothiazoles. 
Experimental:  All chemicals were purchased from Aldrich/Sigma Chemical Company and used as 
received. Anhydrous solvents were also obtained from Aldrich/Sigma in Sure/Seal™ bottles and 
transferred to reaction vessel via cannula under nitrogen atmosphere. Nuclear magnetic resonance 
(NMR) spectra were recorded on a Bruker  400,  500 or 700 , 900MHz instruments and chemical 
shifts are reported in parts per million relative to tetramethylsilane, which was the internal standard. 
13C NMR spectra were recorded in CDCl3 on the same instruments by using proton decoupling 
technique. The chemical shifts reported for 13C NMR spectra are referenced to chloroform at 
77.0ppm. 
p-Aminophenyl benzothiazole: A flask was charged with 30 ml of polyphosphoric acid and heated to 
220⁰C over an oil bath. p-Amino benzoic acid (5.48g, 0.036mole) was added in aliquots and the 
contents were stirred to dissolve the amino benzoic acid to form a homogenous solution. A brown 
solution resulted after the addition of the acid. After this period, 5.0g (0.04mole) of o-
aminothiophenol  was transferred into the mixture when a vigorous reaction took place forming a 
dark brown slurry. The reaction mixture was heated to 220⁰C and stirred for additional 8 hours 
maintaining the temperature. After this period, the mixture was allowed to cool to 100⁰C and the 
viscous dark liquid was carefully poured into a beaker containing 500ml of ice/water mixture. A 
precipitate was obtained which was filtered and washed with 4 x250 ml of water. The resulting solid 
was once again placed in an Erlenmeyer flask and a solution of sodium carbonate (50g/250ml water) 
was added and the mixture was stirred for 1h. The insoluble precipitate was filtered off and washed 
with additional water (2x200ml) and dried under vacuum to yield a light greenish yellow powder. 
The product was further purified by crystallization using methanol/water (80:20) to furnish the 
required p-amino phenyl benzothiazole as light yellow needles (5.4g, 0.22mol, 66% yield). Selected 
IR bands :3429, 3178, 1636, 1604, 1475, 1433, 1312, 1250, 1228, 1182, 1159, 963, 827, 760 cm-1; 1H 
NMR (400MHz) (d6-DMSO), δ ppm: 8.02-7.98 (m, 2H), 7.77-7.73 (d, 2H, J=8.0Hz), 7.45-7.44 (t, 1H), 
7.36-7.31 (t, 1H), 6.69-6.65(d, 2H, J=8.0Hz), 5.89 (s, 2H); ES+ mass: m/z calculated for C13H10N2S: 226; 
found 227 (M+1} 
p-N-methyl aminophenyl benzothiazole:  A similar procedure was adopted for the preparation of this 
compound except  p-N-methyl amino benzoic acid was used  and the greenish grey product was 
further recrystallized using methanol/water mixture (75/25) to obtain dark shiny crystals of the 
desired product (3.5g, 0.014mol, 35% yield). 
IR: 3307, 1654, 1609, 1540,1513, 1466, 1440, 1416, 1342, 1316, 1286, 1255, 1227, 1181, 1161, 1111, 
1074, 1007, 962, 864, 824, 758 cm-1; 1H NMR (200MHz) (d6-DMSO)δ ppm: 8.0-7.89 (m, 2H), 7.84-
7.80(d, 2H, J=8.0Hz), 7.48-7.45 (t, 1H), 7.35-7.28 (t, 1H), 6.66-6.62 (d, 2H, J=8.0Hz), 6.47 (bs, 1H), 3.28 
s, 3H); 13C NMR (d6-DMSO )δ ppm: 168.8, 154.6, 153.2, 134.4, 129.4, 126.9, 124.9, 122.6, 122.4, 
120.7, 112.2, 29.9; EI mass calculated for C14H12N2S: 240, found : 241 (M+1). 
 Mono alkylation of Aminophenyl bezothiazoles: The mono alkylation reaction was achieved using a 
standard procedure described below. The appropriate alkyl iodide/bromide was used for the mono 
alkylation reactions. As an example, to prepare p-N-isopropylamino phenyl benzothiazole, 0.452g (2 
mmol) of p-Amino phenyl benzothiazole was placed in a round bottom flask, 40 ml of acetonitrile 
was added and the contents stirred to form a homogenous solution. To this mixture was added, with 
stirring, 0.3g (2.2 mmol) of anhydrous potassium carbonate. Using a dry syringe, 0.250g (2 mmol) of 
isopropyl bromide was introduced into the flask and the contents were allowed to reflux for 9 hours. 
After completion of the reaction, the contents were cooled to room temperature and the mixture 
was filtered. The solvent was removed under vacuum and the contents were taken up in ethyl 
acetate (30ml) and washed with water and dried over anhydrous sodium sulphate and filtered. 
Rotary evaporation of the solvent gave a residue which was column chromatographed over an 
alumina basic column using hexane/ethylacetate ( 90:10) to obtain the desired compound. (0.136g, 
50% yield). 1H NMR (CDCl3)δ ppm; 7.99-7.96 (d,1H,J=9.0Hz),  7.92-7.89 (d, 2H, J=9.0Hz), 7.85-7.82 
(1H, d, J=9.0Hz); 7.46-7.41 (t, 1H), 7.33-7.26 (t, 1H), 6.63-6.60 (d, 2H, J=9.0Hz); 3.92 (s, 1H), 3.75-3.67 
(m,1H), 1.25-1.24 (d, 3H, J=6.0Hz); EI mass calculated for C16H16N2S : 268, found : 269 (M+1). 
p-N-ethyl- Aminophenyl benzothiazole:  1H NMR (CDCl3)δ ppm: 7.97-7.95 (d, 1H, J=), 7.90-7.88 (d, 
2H, J=), 7.42-7.39 (t, 1H), 7.29-7.26 (t, 1H), 6.63-6.61 (d, 2H, J=), 3.95 (bs, 1H), 3.24-3.20 (m, 2H), 
1.29-1.26 (t, 3H); 13C NMR (CDCl3):δ ppm: 168.7, 154.4, 150.7, 134.5, 129.1, 125.9, 124.2, 122.5, 
122.3, 121.3, 112.3, 38.1, 14.7. 
o-N-ethyl-Aminophenyl benzothiazole:1H NMR (CDCl3) δ ppm:8.85 (bs, 1H), 7.96-7.94 (d, 1H, J=), 
7.87-7.85 (d, 1H, J=), 7.74-7.72 (d, 1H, J=), 7.46-7.43 (t, 1H), 7.36-7.30 (m,2H), 6.79-6.78 (d, 1H, J=), 
6.69-6.67 (t, 1H), 3.40-3.34 (m,2H), 1.44-1.40 (t, 3H); 13C NMR (CDCl3):δ ppm: 169.6, 153.6, 147.5, 
132.0, 130.7, 125.9, 124.7, 122.2, 121.2, 114.9, 111.3, 31.6, 14.6. 
p- N-butyl-Aminophenyl benzothiazole : 1H NMR (CDCl3) δ ppm: 7.97-7.95 (d, 1H, J=), 7.89-7.88 (d, 
2H, J=), 7.82-7.80 (d, 1H, J=), 7.42-7.39 (t, 1H), 7.30-7.28 (t, 1H), 6.63-6.61 (d, 2H, J=), 4.01 (bs, 1H), 
3.18-3.15 (t, 2H), 1.65-1.59 (m, 2H), 1.45-1.41 (m,2H), 0.97-0.94 (t, 3H); 13C NMR (CDCl3):δ ppm: 
168.8, 154.4, 150.8, 134.5, 129.1, 125.9, 124.2, 122.4, 122.3, 121.3, 112.2, 43.2, 31.5, 20.2, 13.9. 
o-N-butyl-Aminophenyl benzothiazole: 1H NMR (CDCl3) δ ppm: 8.93 (bs, 1H), 7.92-7.90 (d, 1H, J=), 
7.85-7.83 (d, 1H, J=), 7.72-7.70 (d, 1H, J=), 7.44-7.42 (t, 1H), 7.33-7.27 (m,2H), 6.78-6.76 (d, 1H, J=), 
6.66-6.64 (t, 1H), 3.32-3.29 (m,2H), 1.80-1.75 (m, 2H), 1.59-1.54 (m,2H), 1.02-0.99 (t, 3H); 13C NMR 
(CDCl3):δ ppm: 147.7, 132.1, 130.7, 125.9, 124.7, 122.2, 121.1, 114.8, 111.3, 42.7, 31.3, 20.5, 13.9. 
o-N-isopropyl-Aminophenyl benzothiazole: The use of potassium carbonate in acetonitrile did not 
yield the required compound. However a modification in the synthetic procedure was adopted for 
this precursor. In a flask was placed 0.113g (0.5 mmol) of o-aminophenyl benzothiazole and 10 ml of 
dimethyl sulfoxide and the mixture was stirred to form a homogenous solution. To this mixture was 
added 20mg (0.5 mmol) of powdered sodium hydroxide resulting into a deep orange brown solution. 
To this was added 0.062g (0.5mmol) of isopropyl bromide and the resulting mixture was stirred at 
room temperature for 6 hours. The contents were added to 50ml of ice/water mixture to obtain a 
precipitate. The precipitated product was extracted with ethyl acetate (50 ml) and the organic layer 
was separated and dried over anhydrous sodium sulphate. Filtration and rotary evaporation yielded 
a residue which was further purified by preparative thin layer chromatography to yield a deep yellow 
product (10% yield). 1H NMR (CDCl3):8.94 (1h< NH), 7.93 (d, J=7.92Hz, 1H), 7.85 (d, J=8.27 (1H), 7.72 
(d, J=8.27Hz, 1H), 7.43 (t, J=7.24Hz, 1H), 7.33 (t, J=7.58Hz, 1H), 7.29 (t, J=7.58Hz, 1H), 6.79 (d, 
J=8.62Hz, 1H), 6.64 (t, J=7.24Hz, 1H), 3.82 (m, 1H), 1.36 (d, J=6.2Hz, 6H); 13CNMR (CDCl3) 169.6, 
153.6, 146.7, 133.1, 132.0, 130.9, 125.9, 124.7, 122.2, 121.1, 114.6, 114.4, 111.8, 43.6, 22.9. 
p-N-dimethyl-Aminophenyl benzothiazole:  This compound was prepared using a similar procedure 
as before except that methyl iodide and p-methy- Aminophenyl benzothiazole was used as reactants 
in the presence of sodium hydroxide in dimethyl sulfoxide. The product was further purified by 
preparative thin layer chromatography using hexane/ethyl acetate (80:20) ( <15% yield) :1H NMR 
(CDCl3)δ ppm: 7.96-7.93 (m, 3H), 7.82-7.80 (d, 1H, J=), 7.42-7.39 (t, 1H), 7.29-7.27 (t, 1H), 6.73-6.71 
(d, 2H) J=), 3.03 (s, 6H); 13C NMR (CDCl3)δ ppm: 168.8, 154.3, 152.1, 134.5, 128.8,125.9, 124.1, 122.2, 
121.3, 111.7, 29.34 
o-N-methyl- aminophenyl benzothiazole : Column chromatography using 100:5 hexane/ethyl acetate 
gave a deep yellow product. (yield <15%). 1H NMR (CDCl3): 8.79 (1H, NH), 7.96 (d,J=7.9Hz, 1H), 7.86 
(d, J=7.8Hz, 1H), 7.73 (d, J=7.7, 1H), 7.44 (t, =7.7Hz, 1H), 7.34 (m, 2H), 6.77 (d, J=8.25Hz, 1H), 6.69 (t, 
J=7.36 1H), 3.04 (d, J=4.96Hz, 3H); 13C NMR (CDCl3) 169.1, 153.2, 148.0, 132.7, 131.7, 130.2, 125.5, 
124.3, 121.8, 120.7, 114.6, 114.3, 110.4, 29.3. 
p-N-crotyl- Aminophenyl benzothiazole: IR : 3399, 3002, 1611, 1529, 1474, 1455, 1336, 1313, 1255, 
1226, 1179, 1123, 1101, 963, 827, 752,1H NMR (CDCl3)δ ppm:  8.0-7.81 (m, 4H), 7.47-7.43 (t, 1H), 
7.34-7.26 (t, 1H), 6.67-6.63 (d, 2H, J=8.0Hz), 5.84-5.51 (m,2H), 3.77-3.74 (d,2H,J=6.0Hz), 1.76-1.71 (d, 
3H); EI mass calculated for C17H16N2S: 280, found : 281 (M+1). 
o-N-crotyl -Aminophenyl benzothiazole was prepared in analogous method to that for the 
preparation of p-N-crotyl- Aminophenyl benzothiazole. 
o-N-crotyl- Aminophenylbenzothiazole: 1H NMR (CDCl3)δ ppm:  9.02 (bs, 1H), 7.96-7.95 (d, 1H, J=), 
7.85-7.84 (d, 1H, J=), 7.74-7.73 (d, 1H, J=), 7.45-7.43 (t, 1H), 7.34-7.32 (t, 1H), 7.30-7.29 (t, 1H), 6.78-
6.77 (d, 1H, J=), 6.69-6.67 (t, 1H), 5.83-5.80 (m, 1H), 5.69-5.67 (d, 1H, J=), 3.92 (d, 2H), 1.76-1.75 (d, 
3H, J=), 13C NMR (CDCl3)δ ppm: 169.6, 153.6, 147.4, 133.2, 132.0, 130.7, 127.7, 127.2, 125.9, 124.7, 
122.3, 121.1, 115.3, 114.7, 111.5, 44.8, 17.88. 
Cyclotron: Carbon-11 was produced as 11CO2 via the 14N(p,α)11C nuclear reaction by irradiating ultra-
pure nitrogen gas containing 0.5 % oxygen with 16 MeV cyclotron produced protons.  The cyclotron 
used is a Cyclone®18 Twin (IBA Molecular) dual ion source, 18 MeV fixed energy, negative ion 
accelerator.  The gas target employed has an aluminium body with a volume of approximately 50 
cm3 and is filled to a pressure of 20 bar at room temperature with target gas.  The target windows 
consist of a 12.5 µm thick titanium foil on the vacuum side and a 500 µm thick aluminium foil on the 
target side which effectively reduces the beam energy delivered to the target gas from 18 MeV to 16 
MeV.  The target yield at saturation is around 4.4 GBq/µA. 
Radiochemistry: Conversion of the cyclotron produced 11CO2 to [11C]methyl iodide and subsequent 
radiolabelling was performed using a Synthra MeI Plus (Synthra GmbH) automated synthesis 
module.  After cyclotron target irradiation, the 11CO2 was transferred to the module and cryo-
trapped using liquid nitrogen with any remaining target gas and unwanted by-products such as 11CO 
directed to waste.  The 11CO2 was then reacted with hydrogen gas at 425◦C over a nickel catalyst to 
form [11C] methane.  The [11C] methane was purified by trapping on Carbosphere® at -120◦C with any 
unreacted 11CO2  directed to waste. [11C]Methane was then released from the trap by heating and 
then reacted with iodide at 750◦C to form the synthon [11C] methyl iodide.  Excess iodine was 
trapped on sodium hydroxide cartridges while the synthon was purified by trapping on Porapak® 
traps.  The synthon was then released from the traps by heating under helium flow and directed to a 
reaction vessel for the radiolabelling reaction.  Typically, 11CO2 was converted to [11C] methyl iodide 
with a yield of 30%. Typically the activity of trapped 11CO2 at the end of the bombardment was 18-
20GBq, the activity obtained after conversion of [11C] methyl iodide was 8-10GBq (at the trap) 
The radiolabelling was conducted as follows: For the [11C] methylation of the aminophenyl 
benzothiazole precursors, 1-2 mg of the compound was weighed and was transferred into the 
reaction vessel containing a stirrer bar. Using a dry syringe, 0.5ml of dimethyl sulfoxide was 
introduced followed by 10-15 mg of anhydrous potassium carbonate and the reaction vessel was 
attached to the automated synthesizer (Figure 1) and the contents were stirred at room 
temperature. [11C] methyl iodide produced from the Synthra automated system was bubbled to the 
reaction mixture for 5 minutes and the temperature of the reaction mixture was heated to 120⁰C 
and held for 5 minutes before transferring to the product vial.  
For the [11C] methylation  of the mono-alkylated aminophenyl benzothiazole precursors, 1-2 mg of 
the sample was introduced into the reaction vessel, followed by 0.5 ml of anhydrous dimethyl 
sulfoxide and then 10 mg of powdered potassium hydroxide was added to the mixture. The reaction 
was stirred at room temperature for 5 minutes and the radiolabelling was conducted as described 
previously. The total time of synthesis from the start to end was 12 minutes.   
 
 
 Figure 1: MeI Plus synthesiser and user interface showing schematic of synthesiser. 
 
HPLC methods: The radiolabeled compounds were further purified using the following HPLC 
methods.  HPLC analysis was performed using a Shimadzu model-LC 20AD instrument having a diode 
array detector, a quaternary pump, thermostatic column compartment, and a radiodetector 
(Bioscan Flow Count with a pin-diode detector) in conjunction with LCsolutions software computer 
operated system. The analytical column used for detection was a Luna (Phenomenex) 5 micron –
reversed phase C-18 column of dimension 150/4.6 mm. The column was maintained at room 
temperature throughout the analysis. Aqueous mobile phase (A): 0.8%TEA (8ml) and H2O (992 ml), 
pH adj ca 7.5 with 85% H3PO4 (ca 2.1 ml). Organic mobile phase (B): MeCN. Flow rate was 
maintained at 1ml/min throughout the analysis. 
Method 1: 0-1min 50% MeCN(solvent B): 50% (solvent A); 1-25 min 50-95%(B); 25-30min 95% (B), 
30-31 min 95-50% (B), 31-33 min 50%(B) 
Method 2: 0-1min 50% MeCN(solvent B): 50% (solvent A); 1-10 min 50-95%(B); 10-17 min 95%(B), 
17-31 min 95-50%(B),31-33 min 50%(B). 
 
  
 Results and discussion:  
Synthesis and Radiolabeling of benzothiazole precursors: 
The synthesis of aminophenyl  benzothiazole was achieved following Scheme 1 : 
 
Scheme 1: Synthesis of [11C]-radiolabeled aminophenyl benzothiazoles 
The o-and p-Aminophenyl benzothiazole precursors were prepared by the condensation of o-
aminothiophenol with corresponding aminobenzoic acid in polyphosphoric acid at 220˚ C.  The mono 
alkylated precursors were prepared by reacting the amino functionality with the corresponding alkyl 
halide. Radiolabeling was achieved by treating the appropriate benzothiazole precursors with [11C]-
methyl iodide.  The identity of the radiolabeled compounds was confirmed by comparing the HPLC 
retention times with those of the cold reference standards. The primary focus of this paper was to 
examine the reactivity of the amino functionality of primary and secondary aminophenyl 
benzothiazole ligands with respect to methylation using [11C] methyl iodide.  Our investigations have 
demonstrated that the radiolabeling of unsubstituted aminophenyl benzothiazole was accomplished 
easily using sodium/potassium carbonate and methyl iodide, however the secondary amino 
compounds required much harsher conditions including higher temperatures, stronger base as well 
as more polar solvent such as dimethyl sulfoxide. Our radiolabeling experiments also demonstrated 
that the [11C] methylation did not occur if bulkier alkyl groups (e.g. isopropyl) were present on the 
amino functionality. This highlights the possibility that steric hindrance impedes entry of the second 
alkyl group in the structure of the molecule. In contrast, when straight chain alkyl groups were 
present on the amino moiety (hydrogen, Methyl, Ethyl), the [11C]–methylation was successful with 
reasonable radiochemical yields. Having gained the insight into the radiolabeling of the precursors, 
we plan to further elaborate this strategy for ortho aminophenyl substituted benzothiazoles to 
assess whether amyloid binding of these derivatives is diminished or enhanced. The existing 
literature is dominated by p and m-substituted aminophenyl benzothiazole derivatives.   
Effect of bulkier groups during dialkylation: 
To further explore the contribution of steric hindrance to difficulties in alkylating o-aminophenyl  
and  p-aminophenyl benzothiazole with bulkier groups, we attempted to synthesize the t-butyl 
group attached aminophenyl benzothiazole. However, the reaction did not yield the required t-butyl 
substituted product.  This may be rationalized due to the formation of elimination products instead 
of substitution. It is also known that at higher temperatures, the elimination product predominates 
as previously proposed 25,26. In this regard we note that alkylation of the o-aminophenyl 
benzothiazoles was also difficult to achieve and yields were very low compared to that for p-
aminophenyl benzothiazoles. We also failed to obtain isorpropyl-o-aminophenyl benzothiazole using 
standard reaction conditions (K2CO3/MeCN). However, we were able to prepare the isopropyl 
precursor with a stronger base (NaOH), albeit in very low yields. In contrast, the straight chain n-
butyl derivatives of both aminophenyl benzothiazoles could be synthesised consistent with the 
notion that bulkier groups hinder alkylation. Further support comes from the relative ease with 
which both o and p- crotyl aminophenyl benzothiazoles could be prepared, presumably due to the 
straight chain nature of the halide.  
Structural effects of aminophenyl benzothiazoles: 
We examined the difference between the structural characteristics of o-aminophenyl benzothiazole 
and p-aminophenyl benzothiazole. Imparting further stability to the molecule, the o-aminophenyl 
benzothiazole forms intramolecular hydrogen bonding with the nitrogen atom of the thiazole ring as 
shown below:  
 
This has been previously proposed by Dey et al27 to account for the solvatochromism of some 
aminophenyl benzothiazole derivatives. According to this proposal, the lone pair of electrons 
associated with the amino group is being forced to be parallel with the π-cloud, thereby increasing 
the resonance character of this group with the benzothiazole moiety.  Greater difficulty in alkylation 
of the o-aminophenyl benzothiazole derivatives compared to p-aminophenyl benzothiazole 
derivatives may be due to the formation of the hydrogen bond in the former; additional energy 
would thus be required to break the bond. A detailed account of the hydrogen bonding 
characteristics and density functional energy calculation is reported elsewhere 28.  
The radiolabeling of the p-aminophenyl benzothiazole with [11C]CH3I went smoothly and the 
required mono alkylated product, the p-N-[11C]methyl amino phenyl benzothiazole, was obtained 
even under mild reaction conditions (e.g. using K2CO3 as the base and dimethyl sulfoxide as the 
solvent). The radiolabeled compound had similar characteristics to the cold material synthesized 
using a similar strategy. The starting material p-aminophenyl benzothiazole had a HPLC retention 
time of approximately 6.0 minutes (method 1). The radiolabeled product had a retention time of 9.3 
minutes and the cold alkylated product showed a consistent retention time of 9.25 minutes 
confirming the radioalkylation of the starting material. 
We next examined the radiolabeling of a crotyl substituted-p- aminophenyl benzothiazole derivative. 
A facile radioalkyation of the crotyl derivative was achieved using [11C ]methyl iodide. (figure 2). The 
smaller hot peak in the chromatogram is due to the cis isomer methylated product (see scheme 2 
below) present in the starting material as shown below (since the Aldrich starting material for this 
compound, (crotyl bromide) is only 87% trans and 13% cis.) 
 
Scheme 2. Representation of cis (minor) and trans (major) isomers of crotyl aminophenyl 
benzothiazoles labelled with [11CH3]. 
The rationale for introducing the crotyl group in the structure of the p-aminophenyl benzothiazole 
was to increase the liphophilicity of the product. We next conducted experiments to radiolabel the 
mono methyl substituted p-aminopheny benzothiazole using a similar strategy. While radiolabeling 
took place, the yield of radiolabeled material was much lower than that for the parent p-
aminophenylbenzothiazole. (figure 3, method 2). We rationalize that the bulkier group attached to 
the amine moiety perhaps causes steric hindrance towards the incoming methyl group and 
therefore lower radiolabeling capacity consistent with our earlier discussion. The cold isopropyl 
substituted aminophenyl benzothiazole showed a retention time of approximately 14 min (method 
2) while the radiodialkylated product showed a retention time of 18 minutes respectively consistent 
with the dialkylated compounds retention time. 
We next focused our attention to radiolabel the p-N-methyl aminophenyl derivative of 
benzothiazole in order to conduct a second alkylation using [11C] methyl iodide. The radiolabeled 
compound which had an HPLC retention time of 9.8 min (method 2). We also see the peak at 7.5 min 
corresponding to the unlabelled starting material. The radiolabeled compound had similar retention 
time (9.8 min) of the cold sample demonstrating that the alkylation did occur and that we were able 
to get reasonable yield of the radiotracer.  
We also examined the radiolabeling of o-aminophenyl benzothiazole precursors with [11C] methyl 
iodide to establish the trend among the derivatives with the structure. Accordingly we chose as a 
start the o-aminophenylbenzothiazole compound. Both o-aminophenyl and p-aminophenyl 
benzothiazoles underwent mono alkylation with radiolabeled methyl iodide and the radioactive yield 
was also comparable. Figure 4 shows the mono alkylated [11C] methyl group attached o-aminophenyl 
benzothiazole. The radiolabeling of this precursor was further confirmed using authentic cold 
precursor. Interestingly, the alkylated compound showed a retention time slightly lower than the 
starting material perhaps due to its polarity and also the change in the position of the amino group 
in the structure of the molecule (see the o-amino and p-amino phenyl benzothiazoles retention 
times). This is further substantiated by a simple thin layer chromatographic profile of p-aminophenyl 
benzothiazole and o-aminophenyl benzothiazole. The former had a  Rf value of 0.24 while the later 
had a Rf value of 0.62 in 20:80 ethylacetate/hexane medium.    We also compared the yield of 
individual tracers of these substituted aminophenyl benzothiazoles and table 1 provides the data. 
For the individual derivatives reported in this paper, experiments were repeated to determine the 
yields. The reported yields are decay corrected yields based on MeI. We have also included the 
literature data for the C-11 PIB compound for the purposes of comparison with our results 29-32. The 
yield of C11-PIB is higher compared to the yield of p-aminophenyl benzothiazole  for mono alkylation 
and this is attributed  either due to the use of weaker base ( K2CO3) in our case compared to stronger 
base (KOH) used for the mono alkylation of C11-PIB 32 or due to the additional activation by the 
presence of ether group in the structure of PIB. From the table values the following trend in the 
radiochemical yield is observed: The p-amino methyl phenyl benzothiazole was obtained with 3±2% 
yield. Among the derivatives, the isopropyl substituted benzothiazole gave the lowest yield both in 
the o and the p- position in the structure. It is also evident from the table values that the dialkylation 
of the para substituted compound showed a yield of approximately 10±7% while the ortho 
substituted compound gave a value of 26±11%.  In a similar fashion, the p-crotyl group substituted 
compound gave a yield of 17±11 % while the ortho compound gave a value of only 0.1%. The trend 
of higher yields for dialkylation versus monoalkylation for both p- and o-amino phenyl 
benzothiazoles may be explained by the use of sodium carbonate for monoalkylation whereas 
dialkylation was conducted using a stronger base such as sodium hydroxide.   
In summary, we synthesized various substituted aminophenyl benzothiazoles and labelled them with 
[11C] methyl iodide using an automated synthesizer. The mono alkylation of the aminophenyl 
benzothiazoles were accomplished using a weaker base like potassium or sodium carbonate while 
the dialkylation of these precursors required a stronger base like potassium hydroxide/sodium 
hydroxide.  In the case of para and ortho amino phenyl substituted benzothiazoles, the dialkylation 
was achieved and the yield of the radiolabel was comparable. Furthermore, the bulkier substituents 
on the aminophenyl benzothiazoles further hampered the dialkyation especially when we 
introduced isopropyl group in the structure of these aminophenyl benzothiazoles. Additionally we 
found that we were unable to synthesize the t-butyl group attached aminophenyl benzothiazoles 
using t-butyl bromide perhaps due to elimination reactions occurring at higher temperatures. 
Attempted preparation of these t-butyl substituted aminophenyl benzothiazole using our 
experimental conditions failed to yield the product. The difficulty in alkylation of the bulkier group 
attached aminophenyl benzothiazoles is rationalized due to steric hindrance caused by the bulkier 
group in the structure. Additionally we surmise that o-aminophenyl benzothiazole forms a hydrogen 
bond with the thiazole nitrogen while the p-aminopheny benzothiazole lacks such a hydrogen bond 
in the structure. It is also possible that the hydrogen bond causes further stability for the o-
aminophenyl benzothiazoles resulting in the difficulty towards dialkylation compared to the p-
aminophenyl benzothiazoles. Further work is in progress to evaluate the amyloid binding 
characteristics of the cold precursors and to examine the ability of the new 11C- radiolabeled 
compounds to cross the blood-brain barrier and to bind to amyloid in the living brain.  
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Figure 2. Chromatogram of hot and cold trace of purified 11C-labeled crotyl-p-aminophenyl 
benzothiazole 
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Figure 3. Chromatogram of hot and cold trace of 11C-labeled methyl –p-aminophenyl benzothiazole  
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 Figure 4. Chromatogram of hot and cold trace of 11C-labeled o-aminophenyl benzothiazole 
Chromatogram
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The percentage yield of radiolabeled compounds based on 11CMeI 
_____________________________________________________________________     
Compound     Yield (decay corrected)  
_____________________________________________________________________   
   3±2.0 
   0.6±0.2 
   10±7.0 
   17±12 
    10±7.0 
   31±5.0 
   0.2±0.1 
   26±11  
  25±10 29-32 
_______________________________________________________________________  
